training programme in pharmaceutical medicine Regulatory affairs

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "training programme in pharmaceutical medicine Regulatory affairs"

Transcription

1 training programme in pharmaceutical medicine Regulatory affairs INFARMED, Lisbon january 2012

2 Regulatory affairs january 2012 LocaL: INFARMED, Lisbon curricular unit Leader: Hélder Mota Filipe, Pharmd, Phd curricular unit co-leader: Graça Freire, Pharmd Lecturers: Stephen W. Cook, Paula Costa, Dinah Duarte, Margarida Menezes Ferreira, Hélder Mota Filipe, Graça Freire, Rosário Lobato, José M. Sousa Lobo, Dina Lopes, Marta Marcelino, Ana Paula Martins, João Cristóvão Martins, Leonor Meisel, Judite Neves, Gonçalo Nunes, Mª João Oliveira, Margarida Oliveira, Fernanda Ralha, Sónia Ribeiro, Bruno Sepodes organisation: Masters in Pharmaceutical Medicine Post-Graduate course in Pharmaceutical Medicine Director: Luis Almeida, MD, PhD, FFPM Deputy Director: Bruno Gago, PharmD, PhD ua.pt) address: Health Sciences Department University of Aveiro Campus Universitário de Santiago Edifício III Aveiro Portugal Tel Fax

3 DAy JANUARy time Programme Lecturer 0. introduction 09h45-10h Overview & objectives Hélder Mota Filipe & Graça Freire (GlaxoSmithKline) 1. overview of the global regulatory environment 10h00-11h00 11h00-11h30 11h30-12h General principles of medicines regulation, and international (WHO, WMA, CIOMS) and national agencies Regulatory management systems in Europe, US, Japan and ROW; Portuguese special regulatory requirements The main EU regulatory bodies Portuguese contribution to the international regulatory environment 1.5. Role of harmonization: International Conference on Harmonisation (ICH Guidelines); EU harmonisation. FDA guidances and EMA directives and guidances. FDA Critical Path Initiative and recent CDER initiatives Coffee-break Sónia Ribeiro (European Medicines Agency) & Hélder Mota Filipe Dina Lopes 12h00-13h Pharmacopeas, INN José M. Sousa Lobo (Faculty of Pharmacy, University of Porto) 13h00-14h00 Lunch 2. Marketing authorisation 14h00-15h30 15h30-16h30 16h30-17h Marketing authorisation applications in major countries/regions (MAA, NDA/BLA, JNDA and CNDA) EU marketing authorisation procedures: centralized, mutual recognition/decentralized; national procedures; procedure flow, timings; regulatory stakeholders; specificities and major differences; Portugal role as Rapp/Co-Rapp and RMS The approval, appeal and referral processes; aspects of confidentiality, transparency and updating 2.4. Fast-track review (exceptional, conditional approval); programs for unmet medical needs (AUE) Abridged applications, line extensions 2.6. MAA dossier. Module 1 Product Information; Summary of Product Characteristics (SmPC) impact on commercial strategy; SmPC Guidelines 2.7. Labelling. Patient Leaflet; guidelines (readability, excipients ) and user testing; QRD Group Marta Marcelino Mª João Oliveira (Roche) Margarida Oliveira

4 DAy JANUARy time Programme Lecturer 3. Medicines for children - Paediatrics regulation 09h00-09h PIP and waiver Art. 46 of Regulation (EC) No 1901/2006 Dinah Duarte 09h45-10h30 4. advanced therapies (atmp), biotechnology and biological products Margarida Menezes Ferreira (CAT/EMA/ INFARMED) 10h30-11h00 11h00-11h45 Coffee-break 5. Medicines for rare diseases - orphan drugs 5.1. Orphan designation application; the Committee for Orphan Medicinal Products (COMP); Community Register of OMP; Orphanet Bruno Sepodes (COMP/EMA) 11h45-12h30 6. Generics and biosimilars Rosário Lobato (CAM/ Faculty of Pharmacy, University of Lisboa) 12h30-13h30 Lunch 13h30-14h30 7. Vaccines Stephen W. Cook (GlaxoSmithKline Biologicals, UK) 8. Herbal and homeopathic medicinal products 14h30-15h Regulatory framework; EU and national requirements Ana Paula Martins (HMPC/EMA/ INFARMED) 15h15-15h45 Coffee-break 9. cosmetics 15h45-17h Regulatory framework; EU and National requirements Judite Neves 10. Medical devices regulations The role of the competent authority and notified body EU, national regulation and global harmonisation Task Force Regulatory and Labelling requirements In vitro diagnostic medical devices Judite Neves

5 DAy JANUARy time Programme Lecturer 11. Post-licensing procedures 09h00-10h Life-cycle management. Variations, renewals Paula Costa (Bial) 10h30-11h Direct healthcare professional communication. Urgent safety measures Gonçalo Nunes (Gilead) 11h00-11h30 Coffee-break 12. Medicinal products for veterinary use 11h30-12h Regulatory framework; EU and national requirements Leonor Meisel 12h30-13h30 Lunch 13. Quality, standards, and inspections 13h30-14h30 14h30-15h00 15h00-16h Quality control, quality assurance and certification systems Manufacture and wholesaler licenses Qualified Person Control of active ingredients Coffee-break Internet sales Counterfeit medicines Parallel import Customer complaints Product defects and recall; product withdrawal procedures Regulatory Inspections Fernanda Ralha João Cristóvão Martins 16h closing remarks Hélder Mota Filipe & Graça Freire (GlaxoSmithKline)

6 Module objectives: To know and understand the global regulatory framework applicable to medicinal products and medical devices. To know the procedures for medicines marketing authorisation. To know the regulatory specificities of medicines for children, advanced therapies, biotechnology and biological products, orphan drugs, generics and biosimilars, vaccines, herbal and homeopathic products, cosmetics, medical devices, and veterinary products. To know how to execute tasks relative to licensing and post-licensing procedures in fulfilment of national and international regulatory requirements. To understand the quality control and assurance systems applicable to manufacturing, distribution and dispense of medicines. Learning outcomes of the Module: After module completion, the participant should be able to: Understand the general principles of medicines regulation and the role of national and international regulatory bodies. Know the regulatory management systems in place in Europe, United States, Japan and other countries, and identify Portuguese special regulatory requirements. Know the Portuguese contribution to the international regulatory arena. Understand the importance of international harmonisation of requirements and procedures. Recognize the requirements and procedures related to submitting a Marketing Authorization Application (MAA) in major countries/regions. Know the different types of marketing authorisation procedures in Europe (centralised, mutual recognition/ decentralised, and national procedures). Understand the approval, appeal and referral processes, and the criticality of confidentiality, transparency and updating. Know the fast-track review (exceptional, conditional approval) and the programmes for unmet medical needs (AUE). Know the contents and purpose of product information, namely the summary of product characteristics (SmPC), labelling and patient leaflet (PL). Know the specific regulation applying to marketing authorisation of medicines for children, advanced therapies, biotechnology and biological products, orphan drugs, generics and biosimilars, vaccines, herbal and homeopathic products, cosmetics, and veterinary products. Know the regulations applying to marketing and labelling of medical devices. Know the post-licencing procedures and life-cycle management. Understand the systems and functions aiming to adequately control and assure the quality of medicines during manufacturing, distribution and dispense of medicines, and know the role of the qualified person (QP). Know the legal context and contents of regulatory inspections. Endorsed by the Associação de Médicos Portugueses da Indústria Farmacêutica Accredited by the Ordem dos Farmacêuticos

PRINCIPLES AND PRACTICES OF MEDICAL DEVICE DEVELOPMENT

PRINCIPLES AND PRACTICES OF MEDICAL DEVICE DEVELOPMENT 0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PHARMATRAIN CENTRE OF EXCELLENCE PRINCIPLES AND PRACTICES OF MEDICAL DEVICE DEVELOPMENT Lisbon,

More information

Training programme in pharmaceutical medicine. Project management The basics life cycle, organization and processes

Training programme in pharmaceutical medicine. Project management The basics life cycle, organization and processes Training programme in pharmaceutical medicine Project management The basics life cycle, organization and processes 10 mar - 12 mar 2011 Project management The basics life cycle, organization and processes

More information

PRODUCT RESEARCH & DEVELOPMENT PROCESS

PRODUCT RESEARCH & DEVELOPMENT PROCESS 0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PHARMATRAIN CENTRE OF EXCELLENCE INTRODUCTORY MODULE: PRODUCT RESEARCH & DEVELOPMENT PROCESS Aveiro

More information

training programme in pharmaceutical medicine Clinical Data Management and Analysis

training programme in pharmaceutical medicine Clinical Data Management and Analysis training programme in pharmaceutical medicine Clinical Data Management and Analysis 19-21 may 2011 Clinical Data Management and Analysis 19 21 MAY 2011 LocaL: University of Aveiro, Campus Universitário

More information

Regulatory approval routes in the European System for Medicinal Products

Regulatory approval routes in the European System for Medicinal Products Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research

More information

From Drug Discovery to First in Humans

From Drug Discovery to First in Humans 0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PharmaTrain Centre of Excellence Non-Clinical Testing, Pharmaceutical & Early Clinical Development:

More information

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any

More information

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY 0 :: 2 v01 x y p.345 B xxx.:: B A x y pval«««[xy] -løøøø xxx.:: øøøø -0.02-0.01-0.00 0.00 0.01 0.02.1.2 A PHARMATRAIN CENTRE OF EXCELLENCE EXPLORATORY & CONFIRMATORY CLINICAL DEVELOPMENT: CLINICAL PHARMACOLOGY

More information

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course BioPharmaceuticals and Advanced Therapies 28-2 September/October 2015 - Auditorium The FCT PhD Programme in Medicines and Pharmaceutical

More information

The European regulatory system for medicines and the European Medicines Agency

The European regulatory system for medicines and the European Medicines Agency The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended

More information

APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION

APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION 2015 ABOUT US Portuguese Pharmaceutical Industry Association Founded in 1975, succeeds the National Guild of the Manufacturers of Medicinal Products

More information

Overview of Authorisation Procedures for Medicinal Products

Overview of Authorisation Procedures for Medicinal Products Overview of Authorisation Procedures for Medicinal Products Updated by Martha Anna Bianchetto, PharmD, MBA OBJECTIVES q q Gain an understanding of the regulatory procedures necessary to grant a medicinal

More information

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. June 2013

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. June 2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Revision 4 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING

More information

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT

ORPHAN DRUG. ORPHAN DRUG & RARE DISEASE DEVELOPMENT: Understanding the U.S. and European Regulatory Landscape & RARE DISEASE DEVELOPMENT : Abstract Today, more than ever, researchers are focused on providing care for the approximately 7,000 rare diseases that may have been overlooked in the past due to the challenges of conducting clinical

More information

MRP & DCP step by steb instructions how to apply and how the procedures are conducted

MRP & DCP step by steb instructions how to apply and how the procedures are conducted MRP & DCP step by steb instructions how to apply and how the procedures are conducted 06 May 2013 Dubrovnik, Croatia Dr. Peter Bachmann Head of Unit Coordination Group European and International Affairs

More information

Questions & answers on signal management

Questions & answers on signal management 23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders

More information

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005 EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/BL D(2002) NOTICE TO APPLICANTS Revision 3 VOLUME 2A Procedures for marketing authorisation CHAPTER 1

More information

U. Nitin Kashyap et al /J. Pharm. Sci. & Res. Vol.5(6), 2013,

U. Nitin Kashyap et al /J. Pharm. Sci. & Res. Vol.5(6), 2013, Comparison of Drug Approval Process in United States & Europe U. Nitin Kashyap, Vishal Gupta *, H. V. Raghunandan Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,

More information

Pharmaceutical Engineering: The Lisbon Masters Program

Pharmaceutical Engineering: The Lisbon Masters Program EAFP Catania June 24-26, 26, 2010 Pharmaceutical Engineering: The Lisbon Masters Program José Menezes, Rogério Gaspar, João Bordado,, José Morais Technical University of Lisbon (Portugal) Faculty of Pharmacy,

More information

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

An FDA Perspective on Post- Approval Change Management for PAT and RTRT An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes

More information

The European Pharmacopoeia and certificates of suitability (CEP)

The European Pharmacopoeia and certificates of suitability (CEP) The European Pharmacopoeia and certificates of suitability (CEP) Your Logo Andrew McMath Ph.D. European Directorate for the Quality of Medicines (EDQM) Presented by: Andrew McMath Scientific Officer, EDQM

More information

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course ADVANCED DRUG DELIVERY March 14-18, 2016 Amphiteater B Lisbon, Portugal The FCT PhD Programme in Medicines and Pharmaceutical Innovation

More information

Compilation of Community Procedures on Inspections and Exchange of Information

Compilation of Community Procedures on Inspections and Exchange of Information EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 3 October 2014 EMA/572454/2014 Rev 17 Compliance and Inspection Compilation of Community

More information

How companies leverage quality and quality certifications to achieve competitive advantage

How companies leverage quality and quality certifications to achieve competitive advantage How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for

More information

REQUIREMENTS FOR NATIONAL AND MUTUAL RECOGNITIONS VMP APPLICATIONS

REQUIREMENTS FOR NATIONAL AND MUTUAL RECOGNITIONS VMP APPLICATIONS 1/13 REQUIREMENTS FOR NATIONAL AND MUTUAL RECOGNITIONS VMP APPLICATIONS 2/13 INDEX PAGE Applicable National Legislation and Community texts 3 Content of the application 3 Marketing authorisations 4 Language

More information

EU Regulatory Procedures Strategic Choices

EU Regulatory Procedures Strategic Choices TOPRA Module 1 EU Regulatory Procedures Strategic Choices A presentation by Connie van Oers, Managing Consultant, Xendo BV ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY PROFESSION Learning

More information

EFPIA Good Practice Revision 1, October 2014

EFPIA Good Practice Revision 1, October 2014 EFPIA Good Practice Revision 1, October 2014 Reducing Risk of Drug Products Shortages Introduction Authorities, industry and healthcare providers have a responsibility to ensure a modern and sustainable

More information

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)

Volume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD) Volume 2B Notice to Applicants Medicinal products for human use Presentation and format of the dossier Common Technical Document (CTD) Introduction Edition June 26 Module 1 Edition May 28 Module 2 Edition

More information

Introduction to ISO Identification of Medicinal Products, SPOR programme

Introduction to ISO Identification of Medicinal Products, SPOR programme 29 November 2016 EMA/732656/2015 Information Management Division Introduction to ISO Identification of Medicinal Products, SPOR programme 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex

More information

Report from the CMDh meeting held on 21-23 September 2015. !!! 3 months to go until the mandatory use of the electronic application form!!!

Report from the CMDh meeting held on 21-23 September 2015. !!! 3 months to go until the mandatory use of the electronic application form!!! Report from the meeting held on 21-23 September 2015!!! 3 months to go until the mandatory use of the electronic application form!!! Pharmacovigilance positions following PSUSA procedure for only nationally

More information

Guidance for Industry. Q10 Pharmaceutical Quality System

Guidance for Industry. Q10 Pharmaceutical Quality System Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation

More information

Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View

Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative

More information

MINISTRY OF HEALTH ORDINANCE

MINISTRY OF HEALTH ORDINANCE MINISTRY OF HEALTH 1798 Pursuant to Article 74, paragraphs 2 and 3, Article 83, paragraph 5 and Article 89 of the Medicinal Products Act (Official Gazette 76/2013), the Minister of Health hereby issues

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration

More information

Official Journal of the European Union. (Acts whose publication is obligatory)

Official Journal of the European Union. (Acts whose publication is obligatory) 27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending

More information

MINISTRY OF HEALTH ORDINANCE ON GRANTING MARKETING AUTHORISATIONS FOR MEDICINAL PRODUCTS I. GENERAL PROVISIONS. Article 1.

MINISTRY OF HEALTH ORDINANCE ON GRANTING MARKETING AUTHORISATIONS FOR MEDICINAL PRODUCTS I. GENERAL PROVISIONS. Article 1. MINISTRY OF HEALTH 1802 Pursuant to Article 26, paragraph 7, Article 43 paragraph 9, Article 51, paragraph 3, Article 52 paragraph 5, Article 53 paragraph 6, Article 56 paragraph 3, Article 60 paragraph

More information

PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs. www.rephine.com

PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs. www.rephine.com PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs www.rephine.com The Market Leader in GMP Audit Reporting PharmAssess audit reports are accepted by all Regulatory

More information

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics

More information

Guide to Fees for Veterinary Products

Guide to Fees for Veterinary Products Guide to Fees for Veterinary Products FIN-G0003-14 04 FEBRUARY 2016 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS

More information

PARTICIPANTS. Workshop Profiling Inspectors for new Challenges

PARTICIPANTS. Workshop Profiling Inspectors for new Challenges PORTUGUESE PRESIDENCY OF THE EUROPEAN UNION Workshop Profiling s for new Challenges Lisboa, Hotel Fénix (3-4 December 2007) PARTICIPANTS AFONSO, Natércio Augusto Garção Professor Faculty of Psychology

More information

PROCEDURE FOR HANDLING RAPID ALERTS AND RECALLS ARISING FROM QUALITY DEFECTS

PROCEDURE FOR HANDLING RAPID ALERTS AND RECALLS ARISING FROM QUALITY DEFECTS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 010-4 3 Appendices 1 January 2011 STANDARD OPERATING PROCEDURE PROCEDURE FOR HANDLING RAPID ALERTS AND RECALLS ARISING

More information

Emergence of Compassionate Use programmes

Emergence of Compassionate Use programmes Emergence of Compassionate Use programmes Rosanna Melchior, PharmD, MS IDRAC, Thomson Scientific Overview What is compassionate use (CU) Overview of CU in Europe Authorities and Sponsors Roles and Responsibilities

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Ref. Ares(2011)1044649-03/10/2011 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Pharmaceuticals SANCO/D3/RSR/iv(2011)ddg1.d3. 1137738 Update 1 October 2011 HANDLING

More information

EMA Update Clinical Trials

EMA Update Clinical Trials EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these

More information

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance

More information

An túdarás Rialála Táirgí Sláinte Health Products Regulatory Authority

An túdarás Rialála Táirgí Sláinte Health Products Regulatory Authority ANNUAL REPORT 2014 CONTENTS 2014 STATISTICS AT A GLANCE 2 CHAIRMAN S STATEMENT 4 AUTHORITY MEMBERS 6 MANAGEMENT COMMITTEE 7 CHIEF EXECUTIVE S REPORT 8 AUTHORISATION, REGISTRATION 18 AND LICENSING ACTIVITIES

More information

Guidelines. of 16.05.2013

Guidelines. of 16.05.2013 EUROPEAN COMMISSION Brussels, 16.05.2013 C (2013) 2804 Guidelines of 16.05.2013 on the details of the various categories of variations, on the operation of the procedures laid down in Chapters, a, I and

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member

More information

QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES

QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate

More information

Scrip Regulatory Affairs

Scrip Regulatory Affairs Topical, authoritative and businesscritical coverage of pharmaceutical and medical device regulatory affairs SCRIP Regulatory Affairs provides you with topical, authoritative and business-critical coverage

More information

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics

More information

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare

More information

Abkürzungen. Anatomisch Therapeutisch Chemischer Code der WHO. Bundesinstitut für Arzneimittel und Medizinprodukte (www.bfarm.de)

Abkürzungen. Anatomisch Therapeutisch Chemischer Code der WHO. Bundesinstitut für Arzneimittel und Medizinprodukte (www.bfarm.de) Abkürzungen AE Adverse Event AMG Arzneimittelgesetz API Active Pharmaceutical Ingredient AR Assessment Report ARD Applicant s Response Document ASMF Active Substance Master File ATC-Code Anatomisch Therapeutisch

More information

Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation)

Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation) Global CompliancePanel Knowledge, a Way Forward 2-day In-person Seminar: Process Validation Guidance Requirements (FDA and EU Annex 15: Qualification and Validation) Los Angeles, CA July 28th & 29th, 2016

More information

QUALITY, SAFETY AND EFICACY ASSESSOR

QUALITY, SAFETY AND EFICACY ASSESSOR Curriculum vitae PERSONAL INFORMATION Javier Alonso Naveda WORK EXPERIENCE March 2014 Present SUPPORT CVMP MEMBER, CENTRALIZED MANAGEMENT PROCEDURES, REFERRALS, QRD, QUALITY ASSESSOR Support to the CVMP

More information

LICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002

LICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002 Fax: 020 7273 0121 To all licence holders and representative associations Dear Sir/Madam Our Ref: MLX/277 15 November 2001 LICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002

More information

Compilation of Community Procedures on Inspections and Exchange of Information

Compilation of Community Procedures on Inspections and Exchange of Information EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE- GENERAL Public Health and Risk Assessment Pharmaceuticals 27 June 2013 EMA/385898/2013 Rev 16 Compliance and Inspection Compilation of Community

More information

Intensive Course on International Trends in Clinical Quality, Risk Management and Patient Safety: Proven Strategies

Intensive Course on International Trends in Clinical Quality, Risk Management and Patient Safety: Proven Strategies International Trends in Clinical Quality, Risk Management and Patient Safety: Proven Strategies Sponsored by: Sharon Kleefield, Ph.D. Healthcare Quality Director, Harvard Medical International, Lecturer,

More information

Administrative Burdens of Regulation Department of Health

Administrative Burdens of Regulation Department of Health Administrative Burdens of Regulation Department of Health 2 ADMINISTRATIVE BURDENS OF REGULATION DEPARTMENT OF HEALTH Administrative Burdens of Regulation Department of Health As part of its strategy for

More information

CLINICAL TRIALS WITH MEDICINES IN EUROPE

CLINICAL TRIALS WITH MEDICINES IN EUROPE CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 8 December 2015 EMA/61341/2015 Guideline on good pharmacovigilance practices (GVP) Module XVI Addendum I Educational materials Draft finalised by the Agency in collaboration with Member States for submission

More information

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory

More information

The PRAC Pharmacovigilance Risk Assessment Committee

The PRAC Pharmacovigilance Risk Assessment Committee The PRAC Pharmacovigilance Risk Assessment Committee Workshop, 17 June 2011, London Presented by: Dolores Montero AEMPS Roberto De Lisa European Medicines Agency An agency of the European Union New Pharmacovigilance

More information

Product information management

Product information management Product information management Zagreb 15-06-2011 Presented by: Alexios Skarlatos Head of Product Information Quality/Medical Information Sector An agency of the European Union Contents Part 1: Review of

More information

20-21 May 2015, Lisbon, Portugal. Highlights. Speakers:

20-21 May 2015, Lisbon, Portugal. Highlights. Speakers: Speakers: Dr Afshin Hosseiny Chair of the ECA Expert Working Group on GDP, Tabriz Consulting Comply with the new EU GDP Guideline Dr Martin Egger Pharmaserv Dr Daniel Müller GMP/GDP Inspector All participants

More information

A critical review of the current. marketing authorisation transfer procedure. in Europe

A critical review of the current. marketing authorisation transfer procedure. in Europe A critical review of the current marketing authorisation transfer procedure in Europe Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen

More information

Clinical research: where are we with the new (Paediatric) RC trial Regulation

Clinical research: where are we with the new (Paediatric) RC trial Regulation where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new

More information

The Quality System for Drugs in Germany

The Quality System for Drugs in Germany The Quality System for Drugs in Germany Prof. Dr. Harald G. Schweim Head of Department for Drug Regulatory Affairs Institute for Pharmacy, University of Bonn Former President of the German Federal Institute

More information

PHARMACEUTICAL QUALITY SYSTEM Q10

PHARMACEUTICAL QUALITY SYSTEM Q10 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step

More information

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG

Regulatory Affairs Graduate & Postgraduate Program. Novartis Pharma AG Novartis Animal Health AG Regulatory Affairs Graduate Postgraduate Program Novartis Pharma AG Novartis Animal Health AG The Regulatory Affairs (RA) Graduate Program is an opportunity to discover the global functions of Drug Regulatory

More information

Harmonised Technical Guidance for ectd Submissions in the EU

Harmonised Technical Guidance for ectd Submissions in the EU Guidance for Industry on Providing Regulatory Information in Electronic Format Harmonised Technical Guidance for ectd Submissions in the EU Version 3.0 August 2013 Page 1 of 60 Table of Contents Table

More information

EMA policy on publication of Clinical Data. SFdS - Journée Annuelle du groupe Biopharmacie & Santé

EMA policy on publication of Clinical Data. SFdS - Journée Annuelle du groupe Biopharmacie & Santé EMA policy on publication of Clinical Data Two main objectives In the interest of public health: To enable public scrutiny - To establish trust and confidence in the system To enable application of new

More information

Boots Pharmaceuticals Bruise Relief Arnica cream THR 01175/0398 UKPAR TABLE OF CONTENTS. Lay summary Page 2. Scientific discussion Page 3

Boots Pharmaceuticals Bruise Relief Arnica cream THR 01175/0398 UKPAR TABLE OF CONTENTS. Lay summary Page 2. Scientific discussion Page 3 Boots Pharmaceuticals Bruise Relief Arnica cream UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Patient

More information

RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS

RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Steps taken after authorisation summary

More information

Overview of the EU CTA Regulatory Framework and Future Direction of the EU Clinical Trial Directive. Features

Overview of the EU CTA Regulatory Framework and Future Direction of the EU Clinical Trial Directive. Features 72 Features STEPHAN REYNIER Project Director Voisin Consulting, France Overview of the EU CTA Regulatory Framework and Future Direction of the EU Clinical Trial Directive Over the last few years, the European

More information

White Paper The EU Clinical Trials Regulation Main Changes and Challenges

White Paper The EU Clinical Trials Regulation Main Changes and Challenges White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...

More information

Safeguarding public health. The British Pharmacopoeia. M Vallender Acting Group Manager, BP & Laboratory Services

Safeguarding public health. The British Pharmacopoeia. M Vallender Acting Group Manager, BP & Laboratory Services The M Vallender Acting Group Manager, BP & Laboratory Services OUTLINE Introduction National Activity European and International Activity Future Slide 2 INTRODUCTION Medicines and Healthcare products Regulatory

More information

EPF Recommendations for a patient-centred implementation

EPF Recommendations for a patient-centred implementation Directive 2011/24/EU on the application of patients rights in cross-border healthcare EPF for a patient-centred implementation Introduction These recommendations have been developed by the European Patients

More information

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.

More information

Lessons for the United States: Biosimilar Market Development Worldwide

Lessons for the United States: Biosimilar Market Development Worldwide Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar

More information

The new EU Clinical Trials Regulation How NHS research and patients will benefit

The new EU Clinical Trials Regulation How NHS research and patients will benefit the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of

More information

Is A QPPV Needed? How to be an EU QPPV What You Need to Know and what s new. 5 th European Forum for QPPV 10 May 2011 London

Is A QPPV Needed? How to be an EU QPPV What You Need to Know and what s new. 5 th European Forum for QPPV 10 May 2011 London How to be an EU QPPV What You Need to Know and what s new 5 th European Forum for QPPV 10 May 2011 London Elspeth McIntosh Director Castle Pharmacovigilance Ltd Keith Wibley Director, Pharmacovigilance,

More information

The EU portal and database

The EU portal and database The EU portal and database ECPC General Assembly - 20 June 2015 Presented by Laura Pioppo Clinical and Non-clinical Compliance Service An agency of the European Union Table of contents Legal basis CT programme

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY

More information

Health Innovation: Future Challenges of Oncology Therapies

Health Innovation: Future Challenges of Oncology Therapies PORTUGUESE ASSOCIATION FOR HOSPITAL DEVELOPMENT Health Innovation: Future Challenges of Oncology Therapies Conclusions. Think Health: The Citizen s Access to Therapeutic Innovation Oncology 8 October 2015

More information

Unedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010

Unedited version adopted by the 45th WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organization 2010 GUIDELINE ON SUBMISSION OF DOCUMENTATION FOR A MULTISOURCE (GENERIC) FINISHED PHARMACEUTICAL PRODUCT (FPP): PREPARATION OF PRODUCT DOSSIERS (PDS) IN COMMON TECHNICAL DOCUMENT (CTD) FORMAT Unedited version

More information

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES 24 OCTOBER 2011 INTRODUCTION 1. THE EUROPEAN CONTEXT Centres of expertise (CE) and European Reference

More information

II. AREA OF INVOLVEMENT OF PATIENTS AND CONSUMERS IN EMEA ACTIVITIES

II. AREA OF INVOLVEMENT OF PATIENTS AND CONSUMERS IN EMEA ACTIVITIES European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use MINUTES OF THE EIGHTH MEETING OF THE EMEA HUMAN SCIENTIFIC COMMITTEES WORKING PARTY WITH PATIENTS' AND CONSUMERS' ORGANISATIONS

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)

More information

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.

Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o. Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This

More information

Manchester Pharmacy School. www.manchester.ac.uk/pharmacy

Manchester Pharmacy School. www.manchester.ac.uk/pharmacy Manchester Pharmacy School Postgraduate study from Continuous Professional Development (CPD), Certificate, Diploma to Masters (MSc) with flexible, modular learning. The University of Manchester has a proud

More information

Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd

Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd Public Assessment Report Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) PL 17901/0254 AstraZeneca UK Ltd 1 LAY SUMMARY Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) This is a

More information

History and Principles of Good Clinical Practice

History and Principles of Good Clinical Practice History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices

More information

MUSIC THERAPY TRAINING PROGRAM

MUSIC THERAPY TRAINING PROGRAM MUSIC THERAPY TRAINING PROGRAM Within the framework of the University Program Socrates-Erasmus of the European Community, the Department of Art, Music and Sport Education of the University of Cádiz and

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration

More information

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies

Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of

More information

Clinical trials regulation

Clinical trials regulation Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update

More information

Work plan for GMP/GDP Inspectors Working Group for 2016

Work plan for GMP/GDP Inspectors Working Group for 2016 21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016

More information

Pharmaceutical Quality Management System: Current Concept

Pharmaceutical Quality Management System: Current Concept Pharmaceutical Quality Management System: Current Concept Neetu Dubey 1, *, Himanshu Gupta 3, R.K. Sharma 2, Nitin Dubey 1, Nidhi Dubey 4 1. IPS Academy, Indore, Madhya Pradesh, India. 2. Prestige Institute

More information